Inventor
WHITEHEAD STEPHEN S
US47 patents
⚠️ This page may combine multiple inventors who share the name “WHITEHEAD STEPHEN S”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
US HEALTH
27 patentsUS7846455B2Dec 7, 2010
Attenuated chimeric respiratory syncytial virus
US HEALTH36 citations93
US6689367B1Feb 10, 2004
Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US HEALTH46 citations93
US5993824ANov 30, 1999
Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
US HEALTH69 citations93
US8039003B2Oct 18, 2011
Recombinant attenuated dengue viruses comprising a deletion in the 3′ untranslated region and additional attenuating mutations induced by chemical mutagenesis
US HEALTH8 citations92
US7560118B2Jul 14, 2009
Attenuated dengue virus comprising mutations in the NS3 gene
US HEALTH8 citations92
US7226602B2Jun 5, 2007
Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
US HEALTH17 citations92
US7517531B2Apr 14, 2009
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
US HEALTH17 citations91
US7709007B2May 4, 2010
Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
US HEALTH18 citations89
US6923971B2Aug 2, 2005
Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US HEALTH15 citations83
US9884104B2Feb 6, 2018
Live attenuated virus vaccines for la crosse virus and other bunyaviridae
US HEALTH3 citations82
US7744902B2Jun 29, 2010
Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes
US HEALTH7 citations73
US10058602B2Aug 28, 2018
Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
US HEALTH3 citations72
US11400150B2Aug 2, 2022
Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
US HEALTH0 citations62
US11318196B2May 3, 2022
Attenuated mutant dengue viruses comprising a mutation in the NS5 non-structural protein
US HEALTH0 citations62
US7842798B2Nov 30, 2010
Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines
US HEALTH3 citations62
US7820182B2Oct 26, 2010
Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
US HEALTH5 citations62
US7662397B2Feb 16, 2010
Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US HEALTH4 citations62
US7465794B2Dec 16, 2008
Polynucleotides encoding recombinant respiratory syncytial viruses expressing immune modulatory molecules
US HEALTH4 citations62
US11753627B2Sep 12, 2023
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
US HEALTH0 citations61
US10500264B2Dec 10, 2019
Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
US HEALTH0 citations52
US10160957B2Dec 25, 2018
Development of dengue virus vaccine components
US HEALTH0 citations52
US10869920B2Dec 22, 2020
Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
US HEALTH0 citations51
US10561724B2Feb 18, 2020
Live attenuated virus vaccines for La Crosse virus and other bunyaviridae
US HEALTH0 citations51
US10456461B2Oct 29, 2019
Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
US HEALTH0 citations51
US10206995B2Feb 19, 2019
Live attenuated virus vaccines for la crosse virus and other bunyaviridae
US HEALTH0 citations51
US7829102B2Nov 9, 2010
Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines
US HEALTH0 citations51
US10837003B2Nov 17, 2020
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4
US HEALTH0 citations50
WHITEHEAD STEPHEN S
6 patentsUS8632782B2Jan 21, 2014
Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3′ untranslated region
WHITEHEAD STEPHEN S10 citations92
US8075903B2Dec 13, 2011
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1, 2, 3, and 4 or antigenic chimeric dengue viruses 1, 2, 3, and 4
WHITEHEAD STEPHEN S14 citations90
US8337860B2Dec 25, 2012
Development of dengue virus vaccine components
WHITEHEAD STEPHEN S6 citations84
US9783787B2Oct 10, 2017
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4
WHITEHEAD STEPHEN S5 citations82
US8298541B2Oct 30, 2012
Live attenuated virus vaccines for La Crosse virus and other Bunyaviridae
WHITEHEAD STEPHEN S6 citations82
US9255252B2Feb 9, 2016
Live attenuated virus vaccines for La Crosse virus and other Bunyaviridae
WHITEHEAD STEPHEN S2 citations61
THE GOVERNMENT OF THE USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES
4 patentsUS12203100B2Jan 21, 2025
Development of dengue virus vaccine components
THE GOVERNMENT OF THE USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES0 citations61
US11746335B2Sep 5, 2023
Development of dengue virus vaccine components
THE GOVERNMENT OF THE USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES0 citations61
US11332722B2May 17, 2022
Development of dengue virus vaccine components
THE GOVERNMENT OF THE USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES0 citations61
US10724007B2Jul 28, 2020
Development of dengue virus vaccine components
THE GOVERNMENT OF THE USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES0 citations51
US GOVERNMENT
2 patentsTHE US SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
2 patentsUSRE46641EDec 19, 2017
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
THE US SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES5 citations83
USRE46631EDec 12, 2017
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
THE US SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES7 citations83
US OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICES
2 patentsUS9090873B2Jul 28, 2015
Development of dengue virus vaccine components
US OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICES5 citations83
USRE45016EJul 15, 2014
Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
US OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICES4 citations83